Specific features of actual infectious diseases in postpandemic period
https://doi.org/10.30629/2658-7947-2024-29-3-66-70
Abstract
The post-pandemic COVID-19 period is characterized by the growth of bacterial infection with septic cause. And different infectious diseases show new specific features in patients with high level of SARS-Cov-2 antibodies. The role of antibody level is not proved. The article presents a clinical observation of a patient with a complicated course of chickenpox, due to an attached bacterial streptococcal infection with a septic course, which led to a fatal outcome.
About the Authors
E. Y. SkripchenkoRussian Federation
St. Petersburg
V. E. Karev
Russian Federation
St. Petersburg
N. V. Skripchenko
Russian Federation
St. Petersburg
К. V. Markova
Russian Federation
St. Petersburg
А. I. Konev
Russian Federation
St. Petersburg
I. B. Petrov
Russian Federation
St. Petersburg
А. V. Golubeva
Russian Federation
St. Petersburg
References
1. On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022 : State report. M.: Federal Service for Supervision of Consumer Rights Protection and Human Welfare. 2023:368. (In Russ.) https://www.rospotrebnadzor.ru/upload/iblock/b50/t4kqksh4b12a2i-wjnha29922vu7naki5/GD-SEB.pdf
2. Afanasyev VV. Cytofl avin in intensive care. A Handbook for Doctors. SPb. 2005. (In Russ.)
3. Vilnits A.A., Skripchenko N.V., Gorelik E.Yu., Egorova E.S., Markova K.V. Possibilities for optimizing pathogenetic therapy of purulent meningitis in children. Journal of Neurology and Psychiatry S.S. Korsakov. 2019;119(12):46–50. (In Russ.)
4. Fedin АI, Rumyantseva SА, Piradov MА, Skoromets АА, Parfenov VА, Klocheva EG et al. The effectiveness of neurometabolic protector cytoflavin in cerebral infarctions (multicenter randomized study). Glavnyj Vrach. 2006;13:13–23. (In Russ.)
5. Yudenkova O, Zhukov V. The use of cytoflavin in the early hours of acute cerebrovascular ischemia. Vrach. 2006;5:67–70. (In Russ.)
6. Laupland KB, Davies HD, Low DE, Schwartz B, Green K, Mc-Geer A. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics. 2000;105(5):E60. doi: 10.1542/peds.105.5.e60
7. Imohl M, Van der Linden M, Reinert RR, Ritter K Invasive group A streptococcal disease and association with varicella in Germany, 1996–2009 FEMS Immunol Med Microbiol. 2011;62:101–109. doi: 10.1111/j.1574-695X.2011.00788.x
8. Boeddha NP, Atkins L, de Groot R, Driessen G, Hazelzet J, Zenz W et al.; EUCLIDS consortium. Group A streptococcal disease in paediatric inpatients: a European perspective. Eur J Pediatr. 2023;182(2):697–706. doi: 10.1007/s00431-022-04718-y
9. Hon KL, Chow TC, Cheung TS, Lam WT, Hung LT, So KW et al. Severe Group A and Group B Streptococcus Diseases at a Pediatric ICU: Are they Still Sensitive to the Penicillins? Curr Clin Pharmacol. 2020;15(2):125–131. doi: 10.2174/1574884714666190926124714
Review
For citations:
Skripchenko E.Y., Karev V.E., Skripchenko N.V., Markova К.V., Konev А.I., Petrov I.B., Golubeva А.V. Specific features of actual infectious diseases in postpandemic period. Russian neurological journal. 2024;29(3):66-70. (In Russ.) https://doi.org/10.30629/2658-7947-2024-29-3-66-70